Skip to main content
Clinical Trials/JPRN-jRCTb040230035
JPRN-jRCTb040230035
Recruiting
Phase 1

A clinical study of bone regeneration using autologous dental pulp stem cells

Yamada Yoichi0 sites5 target enrollmentJune 12, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Yamada Yoichi
Enrollment
5
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 12, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Yamada Yoichi

Eligibility Criteria

Inclusion Criteria

  • (1\) Patients who are capable of making an independent decision to comply with trial requirements and whose informed consents are obtained by oral and written document.
  • (2\) Male and female
  • (3\) Age \>\=20\-years\-old and \<\=70\-years\-old
  • (4\) Patients who have unnecessary and/or discarded teeth such as wisdom tooth, expendientry extracted tooth for orthodontic treatment, supernumerary tooth or displaced tooth without occlusion to supply pulp tissue.
  • (5\) Patients who wish to have dental implant treatment rather than conventional removable prostheses or conserve teeth.
  • (6\) Patients who would require bone transplantation for dental implant because of severe alveolar ridge atrophy. (The width of alveolar bone at the installation sites is \<\= 5 mm. In the maxilla, the distance between the alveolar ridge and the sinus floors is \<\= 5 mm. On the other hand, in the mandible the distance between the ridge and mandibular canal is\<\= 5 mm.) Finally it is decided by CT evaluation.
  • (7\) Patients that oral hygiene is well established.
  • (8\) Patients who are able to visit their hospitals in accordance with the trial schedule.

Exclusion Criteria

  • (1\) Patients who have a difficulty in collecting blood. (hemoglobin content \<11g/dl, blood platelet count \<\=100,000/mm3\)
  • (2\) Patients who suffer from infectious diseases (positive for HBs antigen, HBc antibody, HCV antibody, HIV antibody, HTLV\-1 antibody, and syphilis serology).
  • (3\) Patients with coexisting disorder of the blood, circulatory system, kidney, and/or liver.
  • (4\) Patients taking anticoagulants or antiplatelet agents.
  • (5\) Patients with coexisting diabetes.
  • (6\) Patients with coexisting osteoporosis.
  • (7\) Patients who have mental or consciousness disorder, the history of dependence on alcohol or drugs.
  • (8\) Patients who are either pregnant, possibly pregnant, or who hope to become pregnant during the period of this trial.
  • (9\) Patients who have a previous history of allergy to any antimicrobial agent or local anesthesia.
  • Others who the investigators determined as unsuitable for the trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials